OBJECTIVES: To determine the prevalence and the role of hereditary thrombophilia caused by Factor V Leiden (G1691A), prothrombin G20210A or methylenetetrahydrofolate reductase (MTHFR) C677T gene mutations in recurrent pregnancy loss. MATERIAL AND METHODS: One hundred and nine patients, who were admitted to the 3rd Obstetrics and Gynecology Outpatient Clinic in Goztepe Training and Research Hospital between 2006 and 2008, were included into the study The study group consisted of fifty-seven patients with a history of 3 miscarriages before 20 weeks of gestation and the control group consisted of forty-seven patients with at least one live birth without any history of miscarriage or pregnancy complications. The maternal blood was evaluated for Factor V Leiden (G1691A), prothrombin G20210A and MTHFR C677T gene mutations. RESULTS: No statistically significant difference was found between the study and the control groups in terms of the prevalence of Factor V Leiden (G1691A), prothrombin G20210A and MTHFR C677T gene mutations (p=0.534/ p=0.452/p=0.656, respectively and p<0.05). Furthermore, the prevalence of multiple gene mutations was not statistically different between the groups (p=0.375 and p<0.05) either. CONCLUSION: Routine screening for Factor V Leiden (G1691A), prothrombin G20210A and MTHFR C677T gene mutations in patients with a history of recurrent pregnancy loss is not recommended in Turkish women.
OBJECTIVES: To determine the prevalence and the role of hereditary thrombophilia caused by Factor V Leiden (G1691A), prothrombin G20210A or methylenetetrahydrofolate reductase (MTHFR) C677T gene mutations in recurrent pregnancy loss. MATERIAL AND METHODS: One hundred and nine patients, who were admitted to the 3rd Obstetrics and Gynecology Outpatient Clinic in Goztepe Training and Research Hospital between 2006 and 2008, were included into the study The study group consisted of fifty-seven patients with a history of 3 miscarriages before 20 weeks of gestation and the control group consisted of forty-seven patients with at least one live birth without any history of miscarriage or pregnancy complications. The maternal blood was evaluated for Factor V Leiden (G1691A), prothrombin G20210A and MTHFRC677T gene mutations. RESULTS: No statistically significant difference was found between the study and the control groups in terms of the prevalence of Factor V Leiden (G1691A), prothrombin G20210A and MTHFRC677T gene mutations (p=0.534/ p=0.452/p=0.656, respectively and p<0.05). Furthermore, the prevalence of multiple gene mutations was not statistically different between the groups (p=0.375 and p<0.05) either. CONCLUSION: Routine screening for Factor V Leiden (G1691A), prothrombin G20210A and MTHFRC677T gene mutations in patients with a history of recurrent pregnancy loss is not recommended in Turkish women.